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A B S T R A C T
BACKROUND: Primary percutaneous coronary intervention (PCI) has been shown to 
be a better reperfusion strategy in patients with ST-elevation myocardial infarction 
(STEMI) compared with thrombolysis, particularly when applied early. The objective 
of the present study was to report our experience from treating patients presenting to 
the emergency room of our hospital with STEMI with primary PCI.
PATIENTS AND METHODS: The population of the study included 100 patients who 
presented to our hospital with STEMI and underwent primary PCI over a 12-month 
period. Patients’ clinical and angiographic data were retrospectively collected and pa-
tients were followed up for 9 months. Technical details of the primary PCI, including 
stent implantation, and use of drug eluting stents, thrombus aspiration catheter, or 
platelet glycoprotein IIb/ΙΙΙa inhibitors were recorded and correlated to clinical and 
angiographic patient data.
RESULTS: Of 196 patients who presented o the emergency room with STEMI dur-
ing the study period, 100 (51%) patients (85 men and 15 women) underwent primary 
PCI. PCI was successful with TIMI 3 flow of the infarct-related coronary artery in 79 
(79%) patients. Six (6%) patients died during hospitalization and another 4 (4.3%) pa-
tients died during the 9-month follow up period. Twenty one (22%) patients required 
rehospitalization for acute coronary syndrome, of whom 17 needed a repeat PCI and 
4 patients were submitted to coronary artery bypass grafting. Left ventricular ejec-
tion fraction (LVEF) was <50% in 54 (54%) patients. In 52 patients primary PCI was 
performed in less than 4 hours from onset of symptoms. In his cohort, 19 patients
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were thrombolyzed before arriving to the catheterization laboratory. Antithrombotic therapy with platelet glycoprotein IIb/IIIa 
inhibitors was used in 48 (48%) patients. Univariate analysis showed that the odds of achieving TIMI 3 flow were higher after 
using IIb/ΙΙΙa inhibitors (odds ratio-OR 6.4) or if the LVEF ≥50% (vs LVEF <50%) at the beginning of the PCI (OR 6.4). If the 
time from the onset of symptoms to PCI was >4 hours, the odds of achieving TIMI 3 flow were reduced by 23.4% compared to 
time from symptoms to PCI <4 hours. The presence of TIMI 3 flow of the infarct-related artery reduced the odds of death by 
10.2% compared to the absence of TIMI 3 flow of the infarct-related coronary artery.
CONCLUSION: Our results are in keeping with those published by other groups performing primary PCI. We demonstrated the 
importance of time interval from onset of symptoms until PCI is started. We found that the use of GP IIb/IIIa inhibitors was 
beneficial and emphasized the predictive value of LVEF >50% and the importance of achieving TIMI 3 flow in the IRA at the 
end of the procedure.
I N T R O D U C T I O N
Over the past two decades, cardiologists have witnessed 
and documented the significance of timely opening the occlud-
ed infarct-related coronary artery (IRA) in patients presenting 
with acute myocardial infarction (MI). Several studies1-5 have 
demonstrated that the most efficient way to achieve a good 
result is through percutaneous coronary intervention (PCI). 
The adoption of primary PCI as routine treatment in acute MI 
by most large hospitals represents an important advance in the 
management of patients with coronary artery disease. Patients 
presenting with acute MI, who are treated with primary PCI 
show decreased mortality and suffer less adverse cardiac events 
compared with patients who receive the classical treatment 
with pharmacological reperfusion using fibrinolysis.6,7
In our hospital an interventional team is on-call on a 24-
hour basis and, following the European Society of Cardiology 
(ESC) guidelines for PCI, an attempt is made to routinely man-
age patients presenting to the emergency room with acute MI 
with primary PCI.7 Thus, the objective of the present study was 
to review our experience and report the clinical outcome of the 
first 100 unselected patients who presented to the emergency 
room of our hospital with acute ST-elevation MI (STEMI) 
and were treated with primary PCI.
P A T I E N T S  A N D  M E T H O D S
The population of the study included all patients who pre-
sented to our hospital with ST-elevation myocardial infarction 
(STEMI) and underwent primary PCI over a 12-month period 
starting in October 2004 and ending in September 2005. One-
hundred and ninety-six patients presented to the emergency 
room with STEMI, and of those, 100 (51%) patients were 
transferred to the catheterization laboratory for coronary an-
giography and primary revascularization. Patients’ clinical and 
angiographic data were retrospectively collected and patients 
were followed up for 9 months. During follow-up, patients 
were either seen in the out-patient clinic upon completion of 
9 months or information was collected via a phone interview 
if a visit to our hospital was not possible.
Technical details of the primary PCI, including use of 
balloon, use of a thrombus aspiration catheter, implantation 
of stents, type of stents implanted, i.e. bare metal (BMS) vs 
drug-eluting stents (DES), use of platetel glycoprotein IIb/ΙΙΙa 
inhibitors etc., were left at the discretion of the operator and 
were recorded and correlated with the demographic, clini-
cal and angiographic data. All patients received aspirin and 
clopidogrel prior to the procedure.
In general, vascular access was obtained via the right femo-
ral artery, and when not feasible, the contralateral femoral 
artery or the right brachial artery was used. A 6F diagnostic 
catheter and subsequently a guide catheter of similar size were 
employed. A total of 5000-10000 units of heparin was used dur-
ing PCI and the activated clotting time was monitored during 
and after the procedure. Post-procedure sheath removal was 
allowed when the activated clotting time (ACT) fell below 200 
sec. Use of local hemostatic devices was left at the discretion 
of the operator.
S T A T I S T I C A L  A N A L y S I S
The analyzed dependent variables of our sample were 
the binary (Yes/No) variables of PCI success (TIMI 3 flow at 
the end of the PCI), readmission and death. To enhance our 
analysis, a new binary combined variable was constructed as 
a “total success” variable, deducing its data from the original 
dependent variables. In order to investigate the effect of any 
independent variable on the odds of the events, we used uni-
variate and multivariate logistic regression models. The build-
ing of the multivariate models followed a forward procedure, 
using the likelihood ratio test. After the modelling procedure, 
the Hosmer-Lemeshow goodness of fit statistics was used. 
A p-value<0.05 was considered significant. The Stata™ 8.0 
statistical software was used.
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R E S U L T S
Table 1 shows the demographic and clinical characteristics 
of our study population. Overall 196 patients presented to the 
emergency room with STEMI over the study period. Of these 
196 patients, 100 (51%) underwent primary PCI. These were 
85 male and 15 female patients, of whom 72 were younger 
than 69 years of age, 24 were between 70 and 79 years of age 
and 4 were over 80 years old.
The PCI procedure was considered successful if at the end 
of the procedure a TIMI 3 flow was achieved in the infarct-
related coronary artery (IRA).8 TIMI 3 flow in the IRA was 
obtained in 79 (79%) of the 100 patients at the end of the 
procedure. Six (6%) patients died during hospitalization and 
another 4 (4.3%) patients died during the 9-month follow up 
period. Twenty one (22%) patients required rehospitaliza-
tion for a new event of acute coronary syndrome, of whom 
17 needed a second PCI and 4 patients were submitted to 
coronary artery bypass grafting.
The left ventricular ejection fraction (LVEF) was meas-
ured routinely by echocardiogram in the emergency room. Of 
the 100 patients, 46 (46%) were found to have LVEF ≥50%, 
while the remaining 54 (54%) patients had LVEF<50%. In 
52 patients primary PCI was performed in less than 4 hours 
from the onset of symptoms. Of the 100 patients, 19 were 
thrombolyzed (either with full or half dose thrombolytic agent) 
before arriving to the catheterization laboratory. Antithrom-
botic therapy with platelet glycoprotein IIb/IIIa inhibitors, 
eptifibatide or tirofiban, were used in 48 (48%) patients.
The standard practice in our Institution during primary 
PCI was to treat only the infarct related coronary artery. 
Stent implantation was routinely performed at the culprit 
lesion; however in this group, 7 patients did not receive any 
stent due to unsuccessful PCI, 59 patients received one stent 
and 34 patients had more than one stent implanted. In our 
hospital drug eluting stents (DES) are implanted according 
to the indications published by the ESC guidelines,7 hence in 
this study-group 28 patients received DES. Balloon predila-
tion was performed in 83 patients. In 29 patients a thrombus 
aspiration device was used.
Both single-factor and multi-factor logistic regression 
analysis was applied for the statistical analysis. With regards 
to TIMI 3 flow, univariate analysis showed that the odds of 
achieving TIMI 3 flow after using IIb/ΙΙΙa inhibitors were 
3.48 times higher than if IIb/ΙΙΙa inhibitors were not used. If 
the LVEF was ≥50% at the beginning of the PCI, the odds of 
achieving TIMI 3 flow at the end of the procedure were 6.4 
times higher for the patient than if the LVEF was <50%.
If the time from the onset of symptoms to PCI was >4 
hours, the odds of achieving TIMI 3 flow at the end of the 
procedure were reduced by 23.4% compared to time from 
symptoms to PCI <4 hours. Using death as a single-factor for 
TABLE 1. Clinical and Angiographic Characteristics of 100 
Patients With STEMI Undergoing Primary PCI
Patient Characteristic No. of Patients
Age <69 years 72
Age 70-79 years 24
Age >80 years 4
Women 15
Infarct-related coronary artery
Left main 3
Left anterior descending (LAD) 58
Circumflex 6
Right coronary artery (RCA) 33
LVEF>50% 46
LVEF<50% 54
TIMI 3 flow at end of PCI 79
Time from onset of symptoms to PCI <4 hours 52
Stents 93
DES 28
BMS 65
Number of stents
0 7
1 59
>1 34
Balloon predilation 83
Thrombosis aspiration catheter 29
GP IIb/ΙΙΙa inhibitors 48
Prior thrombolysis 19
Rehospitalization 21
Repeat PCI 17
CABG 4
Total Deaths 10
In hospital 6
BMS= bare metal stent; CABG= coronary artery bypass grafting; 
DES= drug eluting stent; LVEF= ejection fraction; GP= glycoprotein; 
PCI= percutaneous coronary intervention; STEMI = ST-elevation 
myocardial infarction
our statistical analysis we found that the presence of TIMI 3 
flow of the IRA at the end of PCI reduced the odds of death 
by 10.2% compared to the absence of TIMI 3 flow of the IRA. 
An increase of the patient’s age by 1 year conferred an 11% 
increase of the odds of death.
44
HOSPITAL CHRONICLES 4(1), 2009
D I S C U S S I O N
In the present study we report our results and share our 
experience from performing primary PCI in a consecutive 
series of patients who presented with STEMI in our Institu-
tion. In the “Evagelismos” hospital there are two independ-
ent cardiology departments which follow different treatment 
strategies each, for patients with acute MI. One Department 
routinely treats all patients with STEMI with primary PCI, 
whereas the other Department follows a more conservative 
strategy by referring to the catheterization laboratory for 
primary PCI only the hemodynamically unstable patients, 
patients with extended anterior MIs or those patients who do 
not respond to thrombolysis. This is why only 100 (51%) of 
the 196 patients who presented in the Evagelismos hospital 
with acute MI underwent primary PCI. The comparison of 
the strategies applied by the two departments is a subject of 
a different study.
In this study we found that the use of platelet glycoprotein 
IIb/ΙΙΙa inhibitors increases the odds of achieving TIMI 3 flow 
of the IRA. Although the use of these agents is not formally 
recommended by the ESC guidelines for PCI in this group 
of patients, there have been other studies reporting results 
from the use of IIb/ΙΙΙa inhibitors in agreement with our find-
ings.7,10,11 Probably there is a benefit from the use of IIb/ΙΙΙa 
antagonists in primary PCI for patients with STEMI but this 
requires further investigation with larger and randomized 
trials.
There have been several studies emphasizing the impor-
tance of baseline LVEF as a predictive variable of mortality 
after primary PCI as well as a determinant of success for 
primary PCI.12,13 In the present study we found that a good 
baseline LVEF at the beginning of PCI increased the odds of 
achieving TIMI 3 flow at the end of the procedure.
The importance of time from onset of symptoms to PCI is 
pointed out in every report of primary PCI and it is clear that 
the patient should be transferred to the catheterization labora-
tory as soon as possible. In the current study we found that if 
the time from onset of symptoms to primary PCI exceeded 4 
hours, the odds of achieving TIMI 3 flow were severely reduced 
compared to patients who were transferred to the catheteriza-
tion laboratory within the first 4 hours.
The importance of time elapsing from the onset of symp-
toms to the application of the interventional procedure was 
recently shown in a most recent meta-analysis of 22 rand-
omized trials comparing primary PCI with fibrinolysis.9 The 
authors stress the importance of avoiding any delay in the 
interventional treatment, because the longer the delay the 
higher the mortality. Nevertheless, this meta-analysis showed 
that ‘primary PCI proved superior to fibrinolysis, regardless 
of treatment delay’.
Age is an independent predictor of cardiac death after 
primary PCI. This finding has been reported in several stud-
ies and it was true for our patient cohort as well.2,14 Another 
strong independent predictor of mortality after primary PCI 
is TIMI 3 flow of the IRA at the end of the procedure,12 which 
was also true for our study-group.
C O N C L U S I O N
The results from this relatively small observational study 
are in keeping with the results published by other groups per-
forming primary PCI.3,6-9,13,15-20 Transferring the patients to the 
catheterization laboratory as soon as possible is of paramount 
importance in achieving TIMI 3 flow.15,17-20 The use of platelet 
glycoprotein IIb/ΙΙΙa inhibitors before the initiation or during 
the performance of primary PCI increases the odds of achiev-
ing TIMI 3 flow.10,11,15,16 Left ventricular ejection fraction >50% 
is a factor that predicts success of the procedure and good 
long-term results. TIMI 3 flow at the end of the procedure in 
the infarct-related coronary artery is a powerful predictor for 
good long-term results.
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